Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | TNF | P01375 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | GALR3 | O60755 | 3/20 | 0.64 |
| ▸ | NR2F2 | P24468 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | AGER | Q15109 | 1/20 | 0.57 |
| ▸ | APAF1 | O14727 | 1/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2330274 | 0.90 | LMNA (0.69) | LMNATNFPKMHTTTP53 | |
| SCHEMBL229041 | 0.90 | POLB (0.67) | LMNATNFPKMHTTTP53 | |
| SCHEMBL12479063 | 0.89 | TNF (0.65) | LMNATNFPKMHTTTP53 | |
| SCHEMBL10231515 | 0.89 | PKM (0.60) | LMNATNFPKMHTTTP53 | |
| SCHEMBL1520226 | 0.89 | KMT2A (0.62) | LMNATNFPKMHTTTP53 | |
| SCHEMBL760728 | 0.89 | PKM (0.60) | LMNATNFPKMHTTTP53 | |
| SCHEMBL540958 | 0.87 | TNF (0.73) | LMNATNFPKMHTTTP53 | |
| SCHEMBL1022300 | 0.87 | TLR8 (0.69) | LMNATNFPKMHTTTP53 | |
| SCHEMBL1104819 | 0.86 | TNF (0.66) | LMNATNFPKMHTTTP53 | |
| SCHEMBL12604332 | 0.86 | TSHR (0.68) | LMNATNFPKMHTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101772-A1 | Non-metallocenes, method for the production thereof and the use thereof for the polymerisation of olefins | CELANESE VENTURES GMBH (DE) | 2005-05-12 | — | — | US | disclosed |
| EP-1373283-A1 | NON-METALLOCENES, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR THE POLYMERISATION OF OLEFINS | Celanese Ventures GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002066486-A1 | NON-METALLOCENES, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR THE POLYMERISATION OF OLEFINS | CELANESE VENTURES GMBH (DE) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101772-A1 | Non-metallocenes, method for the production thereof and the use thereof for the polymerisation of olefins | CPNE4, CYP4F12, PPOX | LMNA 4565/4885TNF 4482/4885PKM 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.